A class action lawsuit has been filed against Immutep Limited following the discontinuation of its TACTI-004 Phase III lung cancer trial due to futility, causing the company's stock to plummet over 82%. The lawsuit alleges that Immutep misled investors by concealing negative trial data and overstating trial progress, despite internal knowledge of risks that the study would fail. Investors who bought Immutep securities between March 24, 2025, and March 12, 2026, have until July 6, 2026, to file a lead plaintiff motion. The case highlights risks in biotech investments tied to clinical trial outcomes and potential corporate disclosure issues.
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
Elevance Health reported strong Q2 2026 results with earnings per share of $7.45, surpassing analyst estimates of around $6.20. Revenue also exceeded expectations at $49.83 billion, marking consistent quarterly outperformance. The company raised its ...
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
Worldline has announced a conference call to discuss its H1 2026 financial results on July 30, 2026, at 6:30 pm CET. The event will be accessible via webcast, and sell-side analysts can participate in a Q&A session by pre-registering. The press relea...
Ipsen Pharma conducted a share buy-back program from July 6 to July 10, 2026, repurchasing a total of 28,541 shares. The average purchase price during this period was €166.05 per share. This buy-back activity reflects Ipsen's strategy to manage its c...
